Table 4 Site of relapse of LSCLC patients receiving chemotherapy and IMRT
| Characteristic | Arm without CTV n (%) | Arm with CTV n (%) |
|---|---|---|
| No. of eligible patients | 54(100) | 35(100) |
| Relapse site | ||
| Local- relapse # | 9(16.7) | 6(17.1) |
| In-field | 6(11.1) | 4(11.3) |
| In-margin | 2(3.7) | 1(2.9) |
| Out-of-field | 1(1.9) | 1(2.9) |
| Distant metastasis* | 23(42.6) | 18(51.4) |
| Distant alone | 17(31.5) | 13(37.1) |
| Local + distant | 6(11.1) | 5(14.3) |
| Metastasis sites | ||
| Brain | 11(20.4) | 7(20.0) |
| Bone | 8(14.8) | 6(17.1) |
| Liver | 8(14.8) | 3(8.6) |
| Lung | 4(7.4) | 2(5.7) |
| Adrenal gland | 3(5.6) | 1(2.9) |
| Peritoneum LN | 2(3.7) | 3(8.6) |
